Latest News
Vir Biotechnology, Inc.
- Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
- Gilead is teaming up with Vir on solid tumor cancer drugs in a deal worth up to $1.9 billion
- Vir Biotechnology and Gilead collaborate on novel cancer therapeutics
- Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
- Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers
- Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
- Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Vir Biotechnology Appoints David Liu As Chief Medical Officer
- Vir Biotechnology appoints David Liu as chief medical officer
- Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO
- Vir Biotechnology: Astellas Deal Highlights The Platform's Value
- Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
Headlines from the last 30 days, linking to the original publishers. See all market news →